BUSINESS

Trump announces drug pricing deals with India’s Sun Pharma and 8 more drug companies

US President Donald Trump’s administration on Monday announced drug pricing agreements with nine more pharmaceutical companies, expanding its “most-favoured-nation” (MFN) programme aimed at bringing US medicine prices closer to those paid in other developed countries.

The agreements were signed with Sun Pharma, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Teva Pharmaceuticals and UCB.

The latest deals bring the total number of pharmaceutical companies with MFN agreements to 26. The Trump administration said the companies covered by the programme now account for 89% of the US branded drug market.

Under the new agreements, the companies have committed to giving every state Medicaid programme access to MFN prices for their medicines. They have also agreed to offer future innovative medicines in the US at prices comparable to the lowest prices paid in other developed countries.

Trump announced the agreements at an Oval Office event with executives from the companies, describing the price reductions as a major step towards lowering healthcare costs for Americans.

Nine companies join Trump’s drug pricing push

The White House said the nine companies will collectively invest at least $19.6 billion in US manufacturing in the near term. Several have also agreed to donate active pharmaceutical ingredients to the US government’s strategic reserve.

The agreements also include incentives for participating drugmakers. These include tariff relief and protection from certain future drug-pricing measures, although the terms vary by company and the details of the individual agreements have not all been made public.

The latest deals build on agreements reached with 17 major drugmakers, including Pfizer, Eli Lilly and Amgen.

Those earlier agreements included commitments to lower prices for government programmes and, in some cases, make medicines available directly to consumers through TrumpRx, the administration’s drug-discount platform. The new agreements similarly expand access to lower prices, including through Medicaid.

Trump has been pushing drugmakers to align US prices with those paid in other wealthy countries, arguing that American patients pay significantly more for prescription medicines.

Smaller drugmakers had held back

The latest agreements extend the administration’s MFN programme to a group of mid-sized pharmaceutical and biotechnology companies that had been slower to sign deals.

Smaller and mid-sized drugmakers had expressed concerns that agreeing to lower prices could affect their revenues and profitability. Reuters had previously reported that only Astellas had confirmed applying for the Medicaid pricing programme by June, while executives at some other companies questioned whether the financial benefits of joining would outweigh the costs.

The latest agreements bring a wider group of mid-sized pharmaceutical and biotechnology companies into the administration’s pricing programme, including BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB.

However, it remains unclear how much the new deals will ultimately save US patients or the government. Medicaid already receives substantial discounts from drugmakers under existing law, while the full terms and financial impact of the agreements have not been publicly disclosed.

Drug pricing savings remain uncertain

The Trump administration has presented the agreements as part of a broader effort to reduce prescription drug costs. The White House said the Council of Economic Advisers estimates that the administration’s MFN deals could generate $600 billion in savings over the next decade. The estimate is based on the administration’s projections, while the actual impact of the agreements on drug prices remains uncertain.

According to Axios, Public Citizen’s Access to Medicines director Peter Maybarduk said the new agreements were a distraction from the administration’s broader effort to lower US drug prices to levels paid in other wealthy countries.

Source : MSN

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top